BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28583827)

  • 1. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
    Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
    Gastroenterology; 2017 Sep; 153(3):702-710. PubMed ID: 28583827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
    Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
    Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
    Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
    J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
    Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
    JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis.
    Sun J; Sun H; Cui M; Sun Z; Li W; Wei J; Zhou S
    Int Urol Nephrol; 2018 Oct; 50(10):1835-1843. PubMed ID: 29948864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
    Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
    Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients.
    Fu EL; Franko MA; Obergfell A; Dekker FW; Gabrielsen A; Jernberg T; Carrero JJ
    Am Heart J; 2019 Oct; 216():20-29. PubMed ID: 31382219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
    Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
    QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
    Hart E; Dunn TE; Feuerstein S; Jacobs DM
    Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
    Perkins RM; Kirchner HL; Hartle JE; Bucaloiu ID
    Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
    Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
    BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
    Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
    Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
    Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
    BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term change in kidney function and risk of end-stage renal disease.
    Turin TC; Coresh J; Tonelli M; Stevens PE; de Jong PE; Farmer CK; Matsushita K; Hemmelgarn BR
    Nephrol Dial Transplant; 2012 Oct; 27(10):3835-43. PubMed ID: 22764191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Kidney Disease After Acute Kidney Injury Requiring Continuous Renal Replacement Therapy and Its Impact on Long-Term Outcomes: A Multicenter Retrospective Cohort Study in Korea.
    An JN; Hwang JH; Kim DK; Lee H; Ahn SY; Kim S; Park JT; Kang SW; Oh YK; Kim YS; Lim CS; Oh HJ; Lee JP
    Crit Care Med; 2017 Jan; 45(1):47-57. PubMed ID: 27565014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
    Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
    Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
    Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
    PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
    Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
    BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Proton Pump Inhibitors vs Histamine Type 2 Receptor Blockers for Preventing Clinically Important Gastrointestinal Bleeding During Intensive Care: A Population-Based Study.
    Lilly CM; Aljawadi M; Badawi O; Onukwugha E; Tom SE; Magder LS; Harris I
    Chest; 2018 Sep; 154(3):557-566. PubMed ID: 29856970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.
    Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH
    PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.